Purpose: To explore short-term changes in epivascular glia (EVG), macular pigment optical density (MPOD), visual acuity, and retinal thickness after faricimab or aflibercept in treatment-naive eyes with center-involving diabetic macular edema (DME). Methods: This prospective, non-randomized pilot study included 30 eyes with DME and EVG on en face optical coherence tomography. Fifteen eyes received three monthly injections of faricimab 6 mg and 15 received aflibercept 2 mg. The primary exploratory outcome was complete EVG regression after loading. Secondary outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), MPOD, fluid resolution, and resolution of traction-related abnormalities. Results: Complete EVG regression occurred in 12/15 eyes (80.0%) with faricimab and 6/15 (40.0%) with aflibercept (Fisher's exact p = 0.060). Resolution of traction- related abnormalities occurred in 11/15 (73.3%) and 5/15 eyes (33.3%), respectively (p = 0.066). Post-loading CMT was 274.5 ± 61.3 versus 328.7 ± 72.4 µm (unadjusted p = 0.035), MPOD was 0.46 ± 0.07 versus 0.39 ± 0.08 (unadjusted p = 0.017), and BCVA was 0.27 ± 0.14 versus 0.36 ± 0.16 logMAR (p = 0.112). Conclusions: EVG and traction- related outcomes were numerically more favorable with faricimab but were not statistically significant. Exploratory anatomical and MPOD differences require confirmation in larger randomized studies.

Epivascular glia and macular pigment changes after faricimab or aflibercept during the loading phase in diabetic macular edema: a prospective non-randomized pilot study / Cennamo, G., Rinaldi, M., Caporale, E., Iorio, F., Tramontano, D., Costagliola, C.. - In: PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY. - ISSN 1572-1000. - 62:(2026). [10.1016/j.pdpdt.2026.105687]

Epivascular glia and macular pigment changes after faricimab or aflibercept during the loading phase in diabetic macular edema: a prospective non-randomized pilot study

Cennamo, Gilda
Primo
;
Rinaldi, Michele;Caporale, Erica;Iorio, Fabiana;Tramontano, Davide;Costagliola, Ciro
2026

Abstract

Purpose: To explore short-term changes in epivascular glia (EVG), macular pigment optical density (MPOD), visual acuity, and retinal thickness after faricimab or aflibercept in treatment-naive eyes with center-involving diabetic macular edema (DME). Methods: This prospective, non-randomized pilot study included 30 eyes with DME and EVG on en face optical coherence tomography. Fifteen eyes received three monthly injections of faricimab 6 mg and 15 received aflibercept 2 mg. The primary exploratory outcome was complete EVG regression after loading. Secondary outcomes included best-corrected visual acuity (BCVA), central macular thickness (CMT), MPOD, fluid resolution, and resolution of traction-related abnormalities. Results: Complete EVG regression occurred in 12/15 eyes (80.0%) with faricimab and 6/15 (40.0%) with aflibercept (Fisher's exact p = 0.060). Resolution of traction- related abnormalities occurred in 11/15 (73.3%) and 5/15 eyes (33.3%), respectively (p = 0.066). Post-loading CMT was 274.5 ± 61.3 versus 328.7 ± 72.4 µm (unadjusted p = 0.035), MPOD was 0.46 ± 0.07 versus 0.39 ± 0.08 (unadjusted p = 0.017), and BCVA was 0.27 ± 0.14 versus 0.36 ± 0.16 logMAR (p = 0.112). Conclusions: EVG and traction- related outcomes were numerically more favorable with faricimab but were not statistically significant. Exploratory anatomical and MPOD differences require confirmation in larger randomized studies.
2026
Epivascular glia and macular pigment changes after faricimab or aflibercept during the loading phase in diabetic macular edema: a prospective non-randomized pilot study / Cennamo, G., Rinaldi, M., Caporale, E., Iorio, F., Tramontano, D., Costagliola, C.. - In: PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY. - ISSN 1572-1000. - 62:(2026). [10.1016/j.pdpdt.2026.105687]
File in questo prodotto:
File Dimensione Formato  
Epivascular glia and macular pigment changes after faricimab or aflibercept.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 5.23 MB
Formato Adobe PDF
5.23 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1074617
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact